WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle®, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor®, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
Both products were developed by ICON in partnership with a trusted generic manufacturer following an extensive in-depth quality and technical assessment process undertaken by qualified experts in 2005. Both formulations are included in the WHO Interagency List of Essential Medicines for Reproductive Health. ICON is the International Planned Parenthood Federation (IPPF) subsidiary responsible for commodity supply to IPPF member associations.
With this acquisition, WomanCare Global has global rights to Roselle® and Optinor® and a partner in making these branded products available to IPPF's global network of Member Associations located in over 170 countries. WomanCare Global will also market these products to other public and private sector markets around the world using their established global supply chain and logistics network.
"This partnership with WomanCare Global is a significant step forward in expanding access to quality assured generic hormonal contraceptives at competitive prices," said ICON's General Manager, David Smith.
"WomanCare Global is excited about this important strategic alliance with a key partner," said WomanCare Global Chief Operating Officer Saundra Pelletier. "The addition of these 2 new products to our global portfolio will make a significant difference to women around the world who deserve access to high-quality and affordable products. Roselle® and Optinor® will become important options for women."
Vance-Walz debate highlighted clear health policy differences